Vorinostat (suberoylanilide hydroxamic acid: SAHA) is a histone deacetylase inhibitor originally used for cutaneous T-cell lymphoma; however, based on gene expression data for human HER2-positive breast cancer, a new indication for HER2-positive breast cancer was discovered. Here, ERBB2 is linked to breast carcinoma.